THE ROLE OF PSA IN THE DIAGNOSIS AND SCREENING OF BPH

Authors

  • Mire Spasov Faculty of Medical Science, University “Goce Delcev”- Stip, Republic of North Macedonia
  • Hristijan Spasov Graduate Engineer in Biochemistry, Republic of North Macedonia

Keywords:

prostate, total PSA, glycoprotein, prostatic secretion, BPH, Proskar

Abstract

Prostate-specific antigen is a specific glycoprotein secreted by the acini and ducts of the prostate gland. It is secreted by healthy prostate cells in normal concentrations, while cancerous prostate cells secrete it in much higher concentrations. This tumor marker is tissue-specific, that is, it is specific only for prostate diseases when its concentration is many times increased. Reference values for PSA range from 0 - 4 ng/ml. Determining the concentration of tumor markers is for precise monitoring of the success of the applied therapy. Increased PSA values may mean progression and recurrence of prostate disease or inadequate response to the prescribed therapy, while reduced values indicate successfully applied therapy and an adequate response of the body to it. The prostate, as an important part of the male reproductive system, plays a role in the creation of prostatic secretions that mix with the seminal fluid from the testicles and thus sperm is created. Prostatic secretion has a nutritional and protective role for spermatozoa on their way to the egg in the uterus. The prostate is responsible for the production of the male sex hormone dihydrotestosterone (DHT), that is, when testosterone is converted to DHT under the action of the enzyme 5-alpha-reductase in the prostate. The prostate surrounds the ureter, and therefore any disease of it such as BPH causes obstruction, that is, a delay in urination. Therefore, taking care of the general health of men is a very important part of the prevention of this disease. The level of total PSA concentration was examined in healthy male patients and patients diagnosed with BPH. The level of total PSA was also monitored in the same patients treated with appropriate therapy (Proskar, ), and the effectiveness of the prescribed therapy was determined. From the obtained results, we came to the conclusion that in the control group of patients, the levels of total PSA were within normal reference values, while in patients diagnosed with BPH, the values of total PSA significantly increased. In the treated patients with appropriate therapy, a decrease in the levels of total PSA concentration was recorded, which indicates a successfully applied therapy and an appropriate response of the organism to it.

References

Andersson, K.E., & Wein, A.J. (2021). Pharmacologic management of lower urinary tract storage and emptying failure. In: Partin AW, Domochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier:chap 120.

Barry, M.J. (2001). Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. New England Journal of Medicine; 344(18):1373–1377.

Capogrosso, P., Salonia, A., & Montorsi, F. (2021). Evaluation and nonsurgical management of benign prostatic hyperplasia. In: Partin AW, Domochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier:chap 145.

Jain, M.A., Leslie, S.W., & Sapra, A. (2023). StatPearls Publishing; Treasure Island (FL): Oct 26. Prostate Cancer Screening.

Leslie, S.W., Soon-Sutton, TL, R. I. A., Sajjad, H., & Skelton, W.P. (2023). StatPearls. StatPearls Publishing; Treasure Island (FL): Nov 13. Prostate Cancer.

Olsson, H., Nordström, T., Jäderling, F., Egevad, L., Vigneswaran, H.T., Annerstedt, M., & Grönberg, H. (2021). Eklund M, Lantz A. Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols-Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). J Natl Cancer Inst. 113(5): 632-640.

Siegel, R.L., Miller, K.D., Fuchs, H.E., & Jemal, A. (2022). Cancer statistics. CA Cancer J Clin.72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12. PMID: 35020204.

Siegel, R.L., Miller, K.D., & Jemal, A. (2020). Cancer statistics. CA Cancer J Clin. 70(1):7-30.

Vickers, A.J., Gupta, A., Savage, C.J., Pettersson, K., Dahlin, A., Bjartell, A., Manjer, J., Scardino, P.T., Ulmert, D., & Lilja, H. (2011). A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. 20(2):255-61.

Yanai, Y., Kosaka, T., Hongo, H., Matsumoto, K., Shinojima, T., Kikuchi, E., Miyajima, A., Mizuno, R., Mikami, S., Jinzaki, M., & Oya, M. (2018). Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated PSA. Mol Clin Oncol. Dec;9(6):656-660.

Downloads

Published

2025-08-29

How to Cite

Spasov, M., & Spasov, H. (2025). THE ROLE OF PSA IN THE DIAGNOSIS AND SCREENING OF BPH. KNOWLEDGE - International Journal , 71(4), 429–432. Retrieved from https://ojs.ikm.mk/index.php/kij/article/view/7676

Most read articles by the same author(s)

<< < 1 2